MedPath

Investigation to assess the efficacy of benzyl benzoate 10/25% emulsion versus oral ivermectin for scabies treatment

Phase 4
Conditions
B86
Scabies
Registration Number
DRKS00026602
Lead Sponsor
niversitätsklinik für Dermatologie, Paracelsus Medizinische Universität Salzburg (PMU)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
224
Inclusion Criteria

diagnosis of scabies (dermatoscopically confirmed)

Exclusion Criteria

Scabies crutosa
- pre-treatment with topical Benzyl Benzoate XML File Identifier: bekvJUBdLZKFbixLby3v6TN1L5w=
Page 18/28
- use of topical Permethrin (e.g. Infectoscab 5% Creme®) within the last 2 weeks (child <6 years) or 3 weeks (age = 6years)
- sufficient use of oral ivermectin within the last 3 months
- allergy or intolerance agains top. benzyl benzoate Emulsion
- mental disfunction
- pregnancy/breast-feeding
- alcohol abuse

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
cure rate of topical benzyl benzoate versus oral ivermectin in treating scabies
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath